Finance

Lists
Why is RNAC up 3.45%?
Dive Deeper
RNAC:NASDAQ
Cartesian Therapeutics Inc
$7.06
+3.45%
(+0.23) 1D
Oct 9, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNAC...
Open
$6.87
High
$7.16
Low
$6.85
Mkt. cap
213.45M
Avg. vol.
133.34K
Volume
114.55K
52-wk high
$11.00
52-wk low
$5.60
EPS
-$5.94
Beta
0.65
Shares outstanding
30.26M
No. of employees
75
Open
$6.87
High
$7.16
Low
$6.85
Mkt. cap
213.45M
Avg. vol.
133.34K
Volume
114.55K
52-wk high
$11.00
52-wk low
$5.60
EPS
-$5.94
Beta
0.65
Shares outstanding
30.26M
No. of employees
75
News stories
From web sources and news partners
About Cartesian Therapeutics Inc
CEO-
Employees75
Founded2007
HeadquartersFrederick, Maryland, United States
SectorBiotechnology
Websitecartesiantherapeutics.com
Analyst ratings
Based on 6 analysts giving stock ratings to RNAC in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for RNAC in the last 3 months.
Highest
Current $7.06
$44.00 (+523.67%)
Average
$32.60 (+362.08%)
Lowest
$16.00 (+126.79%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$25.00
+254.4%
09/30/2026
Julian Harrison
BTIG
Buy
Maintained
$44.00
+523.7%
09/29/2026
Gil Blum
Needham
Buy
Maintained
$40.00
+467%
09/29/2026
Martin Fan
Wedbush
Buy
Maintained
$38.00
+438.6%
08/18/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
$40.00
+467%
08/11/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Reiterated
$16.00
+126.8%
08/06/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
-
-
08/06/2026
Unknown Analyst
Wedbush
Buy
Maintained
$38.00
+438.6%
06/10/2026
Thomas Smith
Leerink Partners
Buy
Reiterated
-
-
05/27/2026
Matthew Biegler
Oppenheimer
Hold
Reiterated
-
-
03/10/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
452.00K
947.00K
78.00K
-
Cost of goods sold
13.80M
14.69M
19.46M
20.43M
Cost of revenue
13.80M
14.69M
19.46M
20.43M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7.72M
8.20M
7.11M
8.72M
Operating expense
7.72M
8.20M
7.11M
8.72M
Total operating expenses
21.52M
22.89M
26.58M
29.16M
Operating income
-21.07M
-21.94M
-26.50M
-29.16M
Other non operating income
516.00K
702.00K
91.00K
-4.53M
EBT including unusual items
-35.90M
-101.77M
-39.18M
15.77M
EBT excluding unusual items
-19.00M
-19.97M
-25.38M
-33.43M
Income tax expense
-
-9.19M
-
-
Effective tax rate
-
9.03%
-
-
Other operating expenses
-
-
-
-
Net income
-35.90M
-92.58M
-39.18M
15.77M
Net profit margin
-7,942.92%
-9,775.71%
-50,233.33%
-
Earnings per share
-0.73
-2.71
-0.95
-0.96
Interest and investment income
1.55M
1.27M
1.03M
1.10M
Interest expense
-
-
-
-852.00K
Net interest expenses
1.55M
1.27M
1.03M
251.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-20.46M
-21.33M
-25.88M
-28.38M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps